Earlier today, the company announced the enrollment of the first subject in a Phase 3 trial of REG1 in "patients undergoing percutaneous coronary intervention electively or for the treatment of unstable angina or non-ST elevated myocardial infarction." (PR)
Make no mistake, this is a big deal for RGDO, which priced its IPO at $4 last month after initially filing to sell shares at $14-16 — "If I knew why we missed we'd have hit the target goal," CEO David Mazzo tells FierceBiotech.
The IPO did give the company enough money (when combined with an earlier funding round) to get REG1 to an interim analysis, John Carroll says. From there, the hope is that "wary investors will jump into the game in a big way."